[ad_1] Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has engaged Eurofins Scientific, a multinational contract development and manufacturing organisation, to develop and produce its CannQuit medicated chewable products designed to treat nicotine and opioid addiction disorders. CannQuit Nicotine (CannQuit-N) and CannQuit Opioid (CannQuit-O) are combination drug assets with granted patents and patent applications that were transferred to Incannex as a result of its acquisition of APIRx Pharmaceuticals in August this year. “Opioid and nicotine addiction are significant health problems and a major burden on health systems throughout the world,” […]
Read more